Author: Dr Amy Stanway MBChB, Dermatology Registrar, 2005.
Psoriatic arthritis is a painful, inflammatory condition of the joints that usually (but not always) occurs in association with psoriasis of the skin. Up to 40% of people with skin psoriasis have some signs of psoriatic arthritis.
Symptoms of psoriatic arthritis come and go but it is a lifelong condition. It may result in severe damage to the joints and can be as severe as rheumatoid arthritis. Joint deformity and changes on X-rays may be found in approximately 40% of people with psoriatic arthritis.
People with severe psoriatic arthritis have been reported to have a shorter lifespan than average. This correlates with the severity of the joint disease.
Psoriatic arthritis belongs to a group of arthritic conditions called the spondyloarthropathies. Conditions included in this group have similar features and include:
Common features of the above four conditions include:
The main contributing factors to the development of psoriatic arthritis are genetics, immunological factors and the environment.
Psoriatic arthritis causes pain and swelling of joints, and stiffness, particularly in the morning. This may result in reduced mobility and function.
Specific problems include difficulties with using the hands, standing for long periods, and walking. Many patients with psoriatic arthritis have to discontinue or change their work because of the disease.
Other signs and symptoms of psoriatic arthritis include:
Other features that may be seen in association with psoriatic arthritis include:
Psoriatic arthritis usually affects joints in an asymmetrical pattern (that is, different joints are affected on each side of the body). Approximately one third of patients will have spinal and/or sacroiliac (hip) joint involvement and two-thirds will have arthritis affecting the limb joints without spinal disease. The following are common ways in which psoriatic arthritis can present:
People with psoriatic arthritis usually have some skin signs eventually.
Psoriatic arthritis develops after skin psoriasis in approximately 70% of patients. Remaining patients have either a simultaneous onset of skin and joint psoriasis or joint symptoms precede any skin problem. The severity of the skin diseases does not predict the severity of the joint disease.
Plaque psoriasis is the most common form of skin psoriasis seen with psoriatic arthritis. Joint symptoms may flare with a flare in skin psoriasis but quite commonly the skin symptoms behave independently of joint symptoms. Most people with psoriatic arthritis have mild psoriasis.
The diagnosis of psoriatic arthritis is based on symptoms, examination of skin and joints and compatible X-ray findings.
X-ray findings that are characteristic of psoriatic arthritis include:
Other conditions with similar clinical and X-ray findings to psoriatic arthritis include:
There are no diagnostic blood tests for psoriatic arthritis but tests may be done to help confirm the diagnosis and rule out other causes.
Some treatments for joint psoriasis are also effective for skin psoriasis so treatment plans may take both skin and joint disease into account.
Traditionally, psoriatic arthritis has been treated with the safest medication first, using more aggressive treatment only if the first failed. It is now thought that treating the condition more aggressively from the outset may limit the eventual joint damage and disability. At this time it is not known what factors predict whether a person will have progressive joint disease.
If arthritis is mild and limited to a few joints and the skin disease is not severe the skin is treated with topical therapies or ultraviolet light and the joint disease is managed with pain relief (non-steroidal anti-inflammatory drugs, heat and ice), physical therapy, and possibly corticosteroid injections into the joint.
If arthritis involves several joints or is moderate to severe then more aggressive therapy is likely to be needed, such as:
These medications improve symptoms of pain and stiffness but none have been shown to prevent progressive joint damage and all have potential for serious side effects. Methotrexate, ciclosporin, apremilast and leflunomide are drugs that have a beneficial effect on both joint and skin disease.
Biologic response modifiers are drugs made from monoclonal antibodies that target inflammatory mediators and aim to modify specific inflammatory pathways to prevent joint inflammation. Those licensed for use in psoriatic arthritis are:
Most people with psoriatic arthritis will have ongoing problems with arthritis throughout the rest of their life. Remissions are uncommon; occurring in les than 20% of patients with less than 10% of patients having a complete remission off all medication with no signs of joint damage on X-rays.
Features associated with a relatively good prognosis are:
Features associated with a poor prognosis include:
See the DermNet NZ bookstore.
© 2018 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.